June 6, 2023

JOHNSON & JOHNSON VISION PRESENTS NEW CLINICAL DATA ON ACUVUE® OASYS MAX 1-DAY CONTACT LENSES AT BCLA CONFERENCE

New clinical data to be presented on the performance of ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses
Scientific papers and posters cover a range of contact lens technologies and benefits, spanning the benefits of filtering high-energy visible (HEV) light, therapeutic meibomian gland expression and more
Attendees invited to participate in interactive learning opportunities at the Johnson & Johnson Vision booth, including the ACUVUE® Virtual Reality vision experience

LONDON – JUNE 6, 2023 – Johnson & Johnson Vision, a global leader in eye health and part of Johnson & Johnson MedTech, will be presenting a range of new clinical data and learning opportunities for developments in contact lenses at the 2023 British Contact Lens Association (BCLA) Clinical Conference and Exhibition from 9 – 11 June in Manchester, UK.

A platinum sponsor of the event, Johnson & Johnson Vision has prepared two feature presentations, along with a series of free papers and poster sessions available to Eye Care Professionals in attendance. New data examines the technological features of ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses with filtering high-energy visible (HEV) light designed to reduce halos, starburst, and light scatter ^*,†

“We are delighted to be back at BCLA this year and to share new data on the technology behind our ACUVUE® OASYS MAX 1-DAY contact lenses,” said Jacqueline Henderson, President, EMEA, Johnson & Johnson Vision. “We introduced these lenses specifically to address patients’ evolving needs and are pleased to see results showing such a positive impact on vision and comfort.”

ACUVUE® OASYS MAX 1-Day contact lenses are designed with an unprecedented combination of two new technologies¹ to help meet the needs of modern intense lifestyles: TearStable™ Technology and OptiBlue™ Light Filter. TearStable™ Technology is designed to help prolong tear-film stability and retain moisture for exceptional all-day comfort.^2,4,* The OptiBlue™ Light Filter is the highest-level blue-violet filter^‡, with 60% blue-violet light filtering designed to reduce light scatter for exceptional visual clarity, day to night.^5,†,‡

ACUVUE® Virtual Reality vision experience & education at booth #6

Johnson & Johnson Vision’s booth #6 will host a variety of interactive education opportunities and hands-on demonstrations.

Visitors to the booth will be invited to try the ACUVUE® Virtual Reality vision experience with a demonstration on fitting multifocal contact lenses. The new Virtual Reality vision experience is being shared by Johnson & Johnson Vision with Eye Care Professionals across multiple EMEA countries to help improve contact lens learning and training experiences.

Key presentations

The company will also host multiple educational presentations as part of the 2023 BCLA programme, with the opportunity for attendees to hear from leading experts about clinical data and guidance in contact lens innovations:

Fireside chat: the opportunity to support lifelong eye health Friday 9^th June, 9:30 – 10:00 am BST
Johnson & Johnson Vision Booth (#6)
Visit the Johnson & Johnson Vision booth for a discussion on the opportunity to use contact lenses as a unique entry point for engaging patients about eye health.
Hear from Mathilde Beau, Managing Director Western Europe, Johnson & Johnson Vision and Dr. John Buch, John R. Buch, O.D., M.S., F.A.A.O., Senior Principal Research Optometrist, Johnson & Johnson Vision
Moderator: Dr. Rachel Hiscox, Professional Education & Development Manager, UK & Ireland, Johnson & Johnson Vision
Podium Presentation: Latest clinical results with our next-generation daily disposable contact lenses
Friday, 9^th June, 12:40 – 1:00 pm BST & Sunday, 11^th June, 11:00 – 11:20 am BST Exchange Auditorium
Presentation on the technological benefits of new ACUVUE® OASYS MAX 1-Day contact lenses. Recent clinical data on 342 subjects across 19 investigational sites provides outstanding clinical results and illustrates the new technologies behind ACUVUE® OASYS MAX 1-Day contacts.
Presented by: Dr. John R. Buch, O.D., M.S., F.A.A.O., Senior Principal Research Optometrist, Johnson & Johnson Vision and David Ruston, BSc FCOptom, DipCLP, F.A.A.O., FIACLE, Director of Global Education and Development, Johnson & Johnson Vision
Podium Presentation: Surely That Can’t Be True, or Can it?
Friday 9th June, 4:30-5:30pm BST Exchange Auditorium
Advances in contact lens technology since the commercialisation of the first soft lenses in 1971 have been incredible, with significant changes in contact lens materials, frequency of replacement, care systems and lens designs occurring. However, despite the widespread availability of contact lenses, penetration rates for those who need vision correction remain modest and many practitioners seem to hold on to concepts around the potential value of contact lenses that appear based in the dim and distant past and are certainly no longer valid today. This presentation addresses four common “myths and misconceptions” around soft contact lenses using an evidence-based approach that will dispel some of these incorrect assumptions.
Presented by: Professor Lyndon Jones PhD DSc FRSC FCAHS FCOptom FAAO FIACLE FBCLA, Professor, Director for the Centre for Ocular Research & Education, University Research Chair, University of Waterloo; Professor Philip B. Morgan PhD MCOptom FAAO FBCLA, Professor of Optometry, Head of Optometry, Deputy Head of the Division of Pharmacy and Optometry, and Director of Eurolens Research at The University of Manchester; Dr Rachel Hiscox PhD MCOptom FBCLA, Professional Education & Development Manager UK & Ireland, Johnson & Johnson Vision Care
Pavilion Presentation: Maximising Success for your Presbyopic Patients Saturday 10^th June, 1:00 – 1:15pm BST
Exhibitors Pavilion
Becoming presbyopic is no longer the issue it once was for soft contact lens wearers. Advances in materials and designs now mean patients can enjoy better vision, comfort and ocular health than ever before. But how do we ensure our patients get the most from their multifocal contact lenses, particularly when we consider our presbyopes’ increasing lifestyle demands? Please join us for this short presentation to learn how ACUVUE® OASYS MAX 1-Day Multifocal can help meet your patients’ needs!Presented by: Rachel Hiscox PhD MCOptom FBCLA, Professional Education & Development Manager UK & Ireland, Johnson & Johnson Vision Care

Sessions on scientific papers

Six research papers and posters presented at BCLA by Johnson & Johnson Vision will be covered:

Scientific paper sessions

Contact Lens Discomfort
Friday 9^th June, 9:30 – 11:00 am
End-of-day assessment of asymptomatic versus highly symptomatic soft lens wearers Presented by Carole Maldonado-Codina, from University of Manchester
Tear Film
Saturday 10^th June, 3:30 – 5:30 pm
Evaluation of Meibomian Gland Structure and Appearance after Therapeutic Meibomian gland Expression
Presented by Kasandra Swideriska, from the University of Manchester
Presbyopia and Toric
Sunday 11^th June, 9:00 – 11:00 am
- Filtering high-energy visible light in multifocal contact lenses reduces glare disability and glare discomfort without altering color perception
  Presented by Dr. Billy Hammond, Professor of Behavioral and Brain Sciences at the University of Georgia
- Evaluating the impact of an HEV-filtering multifocal contact lens on halos and light scatter Presented by Dr. Lisa Renzi-Hammond, Assistant Professor at the University of Georgia

Scientific posters

Attendees are invited to review two free posters:

An Integrated Analysis of Six Trials Evaluating the Clinical Performance of a New Soft Contact Lens, by Dr. John R. Buch, O.D., M.S., F.A.A.O., Senior Principal Research Optometrist, Johnson & Johnson Vision
Comfort Advantages Demonstrated with a New Soft Contact Lens, by Dr. John R. Buch, O.D., M.S., F.A.A.O., Senior Principal Research Optometrist, Johnson & Johnson Vision

Sustainability

As part of ongoing environmental sustainability efforts, the Johnson & Johnson Vision booth at BCLA is built re-using materials from previous events and is 100% paperless, with all education and marketing materials available electronically. Every time a visitor uses the digital screen to download material, the amount of paper saved will be added to a running total that is visualised on-site through a virtual “living tree” installation.

Conference attendees can visit the Johnson & Johnson Vision Booth #6 to learn more about contact lens technology, research papers and other educational resources.

###

About Johnson & Johnson Vision

At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.

About Johnson & Johnson MedTech

At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Important Safety Information: ACUVUE^® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Contact lenses should not be used in case of eye infections or any other eye conditions, or in case of a systemic disease that may affect the eye. For complete information, including contraindications, precautions and adverse reactions, please consult the Instructions for Use.

* Versus ACUVUE® OASYS 1-Day contact lenses.
† Filtering of HEV light by contact lenses has not been demonstrated to confer any systemic and/or ocular health benefit to the user. The Eye Care Professional should be consulted for more information.
* Versus Dailies Total1®, MyDay® and Infuse®, also significantly lower versus ACUVUE® OASYS 1-Day.
† Versus ACUVUE® OASYS 1-Day contact lenses.
‡ Filtering of HEV light by contact lenses has not been demonstrated to confer any systemic and/or ocular health benefit to the user. The Eye Care Professional should be consulted for more information.
1. JJV Data on File 2022. TearStable Technology Definition.
2. JJV Data on File 2022. Effect on Tear Film and Evaluation of Visual Artifacts of ACUVUE OASYS MAX 1-Day Family with TearStable Technology.
3. JJV Data on File 2022. Material Properties: 1-DAY ACUVUE MOIST, 1-DAY ACUVUE TruEye, ACUVUE OASYS 1- Day with HydraLuxe Technology and ACUVUE OASYS MAX 1-Day with TearStable Technology Brand contact lenses and other daily disposable contact lens brands.
4. JJV Data on File, 2022. CSM Subjective Responses ACUVUE OASYS MAX 1-Day Contact Lenses- Retrospective Meta-analysis.
5. JJV Data on File 2022. Comparative Subjective Claims for ACUVUE OASYS MAX 1-Day lens vs Dailies Total1® and Additional Stand-Alone Claims.

PP2023MLT5778